Lower PSA linked to greater survival with sipuleucel-T in prostate cancer
Sipuleucel-T treatment may be of the most benefit to patients with metastatic castration-resistant prostate cancer who have low prostate specific antigen levels, say US researchers.
No comments:
Post a Comment